Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors.

MLA

Tsimberidou, Apostolia Maria, et al. “Phase 1 First-in-Human Clinical Study of S-Trans,Trans-Farnesylthiosalicylic Acid (Salirasib) in Patients with Solid Tumors.” Cancer Chemotherapy and Pharmacology, vol. 65, no. 2, Jan. 2010, pp. 235–41. EBSCOhost, https://doi.org/10.1007/s00280-009-1027-4.

APA

Tsimberidou, A. M., Rudek, M. A., Hong, D., Ng, C. S., Blair, J., Goldsweig, H., & Kurzrock, R. (2010). Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Cancer Chemotherapy and Pharmacology, 65(2), 235–241. https://doi.org/10.1007/s00280-009-1027-4

Chicago

Tsimberidou, Apostolia Maria, Michelle A Rudek, David Hong, Chaan S Ng, Jessica Blair, Howard Goldsweig, and Razelle Kurzrock. 2010. “Phase 1 First-in-Human Clinical Study of S-Trans,Trans-Farnesylthiosalicylic Acid (Salirasib) in Patients with Solid Tumors.” Cancer Chemotherapy and Pharmacology 65 (2): 235–41. doi:10.1007/s00280-009-1027-4.